Nuvectis Pharma, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
20.05 ^USD	-4.02%		+7.80%	+165.56%

09-24	Nuvectis Pharma, Inc. Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma	CI
09-24	Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation in China for High-Grade Glioma	MT

Published on 06/22/2026 at 09:20 am EDT - Modified on 07/06/2026 at 04:06 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Greetings, and welcome to the Nuvectis Pharma Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It's now my

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

09-24	Nuvectis Pharma, Inc. Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma	CI
09-24	Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation in China for High-Grade Glioma	MT
08-24	Cantor Fitzgerald Initiates Coverage on Nuvectis Pharma With Overweight Rating	MT
08-12	Certain Warrants of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026.	CI
08-12	Certain Stock Options of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026.	CI
08-12	Certain Common Stock of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026.	CI
08-04	Nuvectis Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Nuvectis Pharma Announces Approval Of Ciprocopan in China for Treatment Of Paroxysmal Nocturnal Hemoglobinuria	CI
07-23	Nuvectis Pharma Says Paroxysmal Nocturnal Hemoglobinuria Drug Approved by Chinese Regulator	MT
07-01	Nuvectis Pharma Insider Bought Shares Worth $916,000, According to a Recent SEC Filing	MT
06-30	Top Premarket Decliners	MT
06-30	Nuvectis Pharma Prices $100 Million Secondary Stock Offering; Shares Down Pre-Bell	MT
06-29	Nuvectis Pharma Launches Proposed Public Stock Offering	MT
06-28	Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 2000 Growth-Defensive Index	CI
06-28	Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 2000 Defensive Index	CI